The strongest impairment of cellular viability in our analyses, however, was observed upon treatment with the Pan-ErbB inhibitor afatinib, suggesting that other members of the ErbB family may be involved in EGF-mediated oncogenic signaling in colorectal cancer cells. The gene discussed is EGFR; the disease is colorectal cancer.